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Continuous cell lines from the muscovy duck as replacement for primary cells in 1 
the production of avian vaccines to increase supply security 2 
 3 
Abstract 4 
 5 
Veterinary vaccines contribute to food security, interrupt zoonotic transmissions, and help to maintain 6 
overall health in livestock. Although vaccines are usually cost-effective, their adoption depends on a 7 
multitude of factors. Because poultry vaccines are usually given to birds with a short life span, very low 8 
production cost per dose is one important challenge. Other hurdles are to ensure a consistent and 9 
reliable supply of very large number of doses, and to have flexible production processes to 10 
accommodate a range of different pathogens and dosage requirements. Most poultry vaccines are 11 
currently being produced on primary avian cells derived from chicken or waterfowl embryos. This 12 
production system is associated with high costs, logistic complexities, rigid intervals between harvest and 13 
production, and supply limitations. We investigated whether the continuous cell lines Cairina retina and 14 
CR.pIX may provide a substrate independent of primary cell cultures or embryonated eggs. Viruses 15 
examined for replication in these cell lines are strains associated with, or contained in vaccines against 16 
egg drop syndrome, Marek's disease, Newcastle disease, avian influenza, infectious bursal disease and 17 
Derzsy's disease. Each of the tested viruses required the development of unique conditions for 18 
replication that are described here and can be used to generate material for in vivo efficacy studies and 19 
to accelerate transfer of the processes to larger production volumes. 20 
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Introduction 26 
 27 
Animal infectious diseases are a cause for losses to biodiversity [1] and a risk to human health due to 28 
zoonosis [2–4]. Infectious diseases that threaten livestock can also lead to economic damages and 29 
contribute to persistent poverty [5–7]. Vulnerability is enhanced by an epidemiological environment that 30 
consists of a high and dynamic annual population of 40 billion chickens (+turkey duck), high density of 31 
animals in intensive farming, contact of free-range and wild animals of different species, potential for 32 
coinfection with different pathogens and different strains of the same pathogen, and legal and illegal 33 
trade with live birds and poultry products across continents [14–16]. 34 
 35 
Vaccines for humans [17,18] and animals [19,20] are an efficacious and economic intervention for the 36 
control of infectious diseases. Veterinary vaccines are also perceived as the ethically and 37 
epidemiologically preferred approach to avoid mass slaughter and culling of animals [21,22].  38 
 However the utilization of an animal vaccine depends on its zoonotic capacity, virulence and 39 
transmissibility of the pathogen in animal populations, potential effects on livestock productivity,  and 40 
not at least marketability. 41 
Such complex considerations also apply for poultry diseases with one consequence that the supply of 42 
vaccines is optimized for industrial, but less so for non-commercial and semi-intensive livestock poultry 43 
keepers. Cost of vaccines and risk to supply is furthermore increased if the production depends on 44 
embryonated chicken eggs. For certain avian virus production, the preparation of the primary chicken 45 
cells is reported to account for approximately 30 % of the total production costs [26], and such issues do 46 
affect poultry farmers with low resources [27].  47 
We have investigated  alternative options  to substitute existing primary cell and embrionated egg based 48 
production of poultry vaccines on a reduced cost. The described technologies are based on the 49 
continuous cell lines CR and CR.pIX that were obtained by biochemical immortalization of primary retina 50 
cells of the domesticated muscovy duck. A detailed summary of the design and development of the two 51 
avian cell lines has been published previously [28]. The cells were shown to be free of adventitious 52 
agents, and sensitive assays against reverse transcriptase suggest that the anatine cell lines (as opposed 53 
to galline cells) do not release active endogenous retroviral particles [29,30]. The cell lines have 54 
furthermore been adapted to suspended proliferation in chemically defined medium, and propagation of 55 
recombinant and wild type viruses of different families to very high yields has been demonstrated [31–56 
35]. This publication describes the production parameters for additional animal viruses that can be used 57 
as vaccines against poultry diseases, namely egg drop syndrome, infectious bursal disease (this is kind of 58 
misleading since IBV does not replicate), infectious bronchitis, Marek's disease, Newcastle disease and 59 
avian influenza. 60 
 61 
Results and discussion 62 
 63 
Egg drop syndrome 64 
 65 
Egg drop syndrome EDS-76 is caused by a member of the Atadenovirus genus in the Adenoviridae family 66 
[36], viruses with double-stranded genomic DNA enclosed by an icosahedral capsid without lipid 67 
membranes. Synonymous names for EDSV are duck adenovirus 1 (DAdV-1) and Duck atadenovirus A (the 68 
name proposed by the ICTV). The natural hosts appear to be ducks and geese and the virus has a world-69 
wide distribution. Clinical disease in poultry often is subacute and only evident in the production of 70 
fewer eggs (the "egg drop") and disturbances in pigmentation and shell quality. Transmission of DAdV-1 71 
occurs vertically and horizontally via orally ingested fomites. 72 
 73 
Adherent CR.pIX cells are permissive for DAdV-1 but overt CPE develops only 5 days post infection and 74 
sometimes it is too weak for clear identification of infection (Figure 1 (a)). A subpassage of the infected 75 
cells usually elevates CPE and titers significantly (data not shown). This observation suggests that DAdV-1 76 
may require an active cell cycle and may have difficulties to spread in cultures that have settled into the 77 
plateau phase. Augmentation of virus replication by subcultivation may also indicate that mixing and 78 
reseeding of the cell monolayer disperses infectious units that are not easily shed into the supernatant. 79 
 80 
DAdV-1 replication in suspension cultures was investigated because such production processes can be 81 
scaled more easily to large volumes and are therefore preferred to adherent cultures. However, yields in 82 
single-cell suspensions were below those obtained in the adherent cultures. We have observed such a 83 
phenomenon previously during the development of a production process for poxviruses and have 84 
induced suspended cell aggregates to augment transmission of the cell-associated infectious units [32]. 85 
The aggregates were formed by addition of a chemically defined virus production medium at the time of 86 
infection [32]. DAdV-1 production may have also benefited from this culture format if spread of cell-87 
associated infectious units contributes to yields. To test this model we compared yields after feed with 88 
virus production medium (aggregation inducer) or with cell proliferation medium (that maintains single-89 
cell culture formats). As virus titers still remained below expectation in both regimens we next 90 
investigated effects of addition of either medium 2 days or 3 days PI, respectively. This time there was a  91 
significant (I see only 2-3 times increase) effect that suggested that virus production medium should be 92 
added 2 days PI (Figure 1 (b)), neither earlier nor later. We currently have no satisfying explanation for 93 
this observation and speculate that inoculation and production phases may have different requirements 94 
for DAdV-1 in our cell and medium combination. Virus attachment to host cells may be more efficient in 95 
single cell suspensions in the initial phase of production as few viruses (at low MOIs) are inoculated into 96 
the culture. Subsequent virus generations are released to much higher MOIs relative to the uninfected 97 
cells. In this later phase it may be beneficial to induce aggregates that include a single or very few 98 
infected cells and a majority of yet uninfected, potential host cells. If the ratio of infected (still viable) 99 
and uninfected cells is important for productive aggregate induction then such a scenario would also 100 
explain the importance of timing.  101 
 102 
The next set of optimizations focused on MOI and cell density at the time of infection (Figure 1 (c)) and 103 
revealed that a MOI of 0.01 (as opposed to 0.1) at intermediate cell densities (2 × 106/mL) should be 104 
optimal for subsequent refinements. Because of the relatively slow replication kinetic we also used qPCR 105 
to follow the dynamic of genome replication in parallel to that of the infectious units. Using a calculation 106 
described previously for relative quantification of gene expression [37] we confirmed a robust 107 
amplification of the viral genome over almost 4 orders of magnitude under the selected conditions 108 
(Figure 1 (c)). 109 
 110 
Replication at different temperatures (33, 37 and 39 °C) was studied with the intention to further 111 
improve viral titers (Figure 1 (d)). DAdV-1 replicated to high titers at 37 °C and 39 °C (the core 112 
temperature of ducks is 41 °C) but appeared not to be able to be propagated efficiently at 33 °C. We 113 
noted a surprising discrepancy between infectious and haemagglutinating units (HAU) that suggests that 114 
a measurable amount of non-infectious particles with HA activity are formed at 33 °C. Replication may be 115 
slightly faster at 39 °C because HA activity indicative of particle formation is higher 24 h PI but this head 116 
start appears not to be maintained at later time points. Stability of EDSV appears to be slightly lower at 117 
the higher temperature and therefore the optimal temperature for production of DAdV-1 was chosen to 118 
be 37 °C. 119 
 120 
An overlay of the optimized process in flasks and a bioreactor (Figure 1 (e)) confirms scalability and good 121 
replication of DAdV-1 at MOI of 0.01 with 2 × 106 CR.pIX cells/mL, at 37 °C. Maximum yields were 6.8 × 122 
107 TCID50/mL, > 1:2
15 HAU/100 µL and 3000-fold amplification of the viral genome (relative to 2 h PI). 123 
 124 
 125 
 126 
 127 
Figure 1. Propagation of DAdV-1 in CR.pIX cell lines. (a) Infection of  adherent cell monolayers is visible only by 128 
immunofluorescence staining 3 days PI but virus spreads efficiently until 5 days PI. (b) Efficient replication in suspension 129 
cultures requires addition of an aggregation-inducing medium 2 days PI. The reference is a culture without feed, SCS was 130 
given cell proliferation medium and AGG virus production medium 2 days PI. (c) Effect of MOI on infectious yields (left panel) 131 
and amplification of genomic DNA (right panel). The viral genome burst number was calculated from the ratios of viral 132 
genome to cellular E1A gene for each time point relative to the ratios at day 0.(what is 0.8, 2 and4??? cell density) (d) 133 
Propagation at 33 °C does not release infectious units but appears to lead to a measurable amplification of antigen (HAU, 134 
right panel). Optimal temperature was determined to be 37 °C. (e) The final process scaled to bioreactors. Comparison of 135 
yields of infectious units, hemagglutinating activity and genome amplification in bioreactors and shake flasks. CPE, cytopathic 136 
effect; PI, post infection; SCS, single cell suspension; AGG, suspended aggregate culture format; HAU, hemagglutinating units. 137 
 138 
Newcastle disease 139 
 140 
Newcastle disease (ND) is caused by a negative-stranded RNA virus of the Avulavirus genus in the 141 
Paramyxoviridae family. NDV is also referred to as serotype 1 in the group of avian paramyxoviruses, 142 
APMV-1. Infectivity of the viruses is augmented by proteolytic processing of the F0 precursor protein in 143 
the viral envelope. This cleavage is catalysed by host proteases and is strongly influenced by the number 144 
of basic amino acids at the cleavage site [38]. Glycoproteins of highly virulent (or velogenic) strains are 145 
cleaved by a greater diversity of proteases, a property that broadens the tropism and allows viruses to 146 
spread more easily within an infected animal and to induce greater damage to organs and tissues [39]. 147 
 148 
ND caused by velogenic strains is a highly contagious disease associated with a significant economic 149 
burden [40]. NDV has a very broad host range and is capable of zoonosis but symptoms caused in 150 
humans even by velogenic strains are usually restricted to a mild and transient conjunctivitis or laryngitis 151 
[41]. 152 
 153 
The vaccine against ND in poultry consists of live, vectored live and killed preparations of lentogenic 154 
strains [40]. Live or vectored live vaccines are often preferred because they can be applied directly in the 155 
hatchery using automated vaccination equipment. NDV has also the highly promising capacity to 156 
replicate in human tumors and is being tested to augment therapies against neoplastic diseases [42]. 157 
However, because this inherent oncolytic activity correlates with virulence in birds, research on and 158 
application of NDV-based virotherapy is being restricted by federal regulation (9 CFR Part 121 i guess) in 159 
the USA.  160 
Most NDV vaccines are produced in embryonated eggs that naturally contain the proteases required for 161 
activation of lentogenic viruses [43–45]. As expected, exogenous trypsin had to be added to CR.pIX 162 
cultures for replication of the lentogenic NDV LaSota (Figure 2 (a)). Because adherent CR and CR.pIX cells 163 
dislodge easily if they are cultivated without supplementation with bovine serum (that would interfere 164 
with the activity of trypsin) we did not further investigate replication in this culture format. 165 
 166 
However, infection of CR.pIX suspension cultures yielded NDV at the lower range of titers reported for 167 
other continuous cell lines even in the presence of trypsin. Although titers are difficult to compare 168 
because infectious units are given in different units it appears that volumetric yields are generally higher 169 
in eggs than in cell cultures (>109 EID50/mL in eggs [46,47], 10
8.5 PFU/mL in LSCC-H32 and secondary 170 
chicken embryo cells [48], 106.1 to 107 TCID50/mL in QT35 [46] and DF-1 cells [47], respectively). Trypsin is 171 
not expected to be inhibited because the chemically-defined cell proliferation medium for CR and CR.pIX 172 
cells has a negligible low protein content (10 ng/mL of recombinant IGF) and no hydrolysates or other 173 
substances that may inhibit proteases. 174 
 175 
We next suspected that the chemically defined proliferation medium should be supplemented with 176 
cholesterol because this compound is not present in the medium but has been reported to be essential 177 
for NDV replication [49]. However, biosynthesis of cholesterol by CR.pIX cells appears to be either 178 
sufficient or not the main limitation as no increases in yields were observed by supplementation. 179 
Cholesterol supplementation may add further complexity to a final production process and was 180 
therefore not included in subsequent experiments. 181 
 182 
Passage of NDV in CR cell suspensions was performed next to investigate whether low titers in cell 183 
cultures are due to adaptation of our strain of NDV to eggs. A 1000-fold increase in infectious titers was 184 
indeed observed between passages 4 and 7 and appeared to remain stable for at least 2 additional 185 
passages (Figure 2 (b)). A direct comparison of virus isolates at passage levels 4 and 9 indicated that 186 
replication kinetics has also increased (Figure 2 (c)). We observed no decrease in titers even at 9 × 106 187 
cells/mL indicating that NDV production may also be possible also at very high densities (there is no cell-188 
density effect, [35] and references therein) although this may not further increase absolute yields. 189 
Further optimization resulted in a process with incubation temperature of 33 - 35 °C, pH of 7.1 units, and 190 
cell density of 2 × 106 /mL. The optimal trypsin concentration is 0.5 µg/mL and should be maintained by 191 
daily or continuous  supplementation. 192 
 193 
A very low (rather than higher) MOI appears to be the most critical parameter for production of the NDV 194 
at passage level 4 (Figure 2 (d)). Titers remained above 108 TCID50/mL for virus at passage level 9 at MOI 195 
from 10-4 down to 10-7. Infectious units with virus at passage level 9 in the improved process are in the 196 
upper range of those reported for continuous cell lines and replication at lowest MOI spans almost 9 197 
orders of magnitude. However, hemagglutinating (HA) activity was still low with maximum values usually 198 
in the range of 1:265 to 1:512/100 µL. To further improve yields we paid more attention to the clumping 199 
of the cells that sometimes occurred 24 h post infection. This phenomenon may reflect formation of 200 
syncytia and provides an additional mechanism for spread of infectious units [50]. We therefore added 201 
virus production medium to further augment the aggregate formation [32], but we also sonicated the 202 
final lysate to separate clusters of cell debris and viruses, speculating that the true HA titers are 203 
decreased proportionally to the number of particles bound within the aggregates. These additional steps 204 
are compatible with scalable processes in bioreactors (Figure 2 (e) and [32]) and did improve HA yields 205 
(Figure 2 (f)). The final process consists of supplementation with 1/6th of the culture volume with virus 206 
production medium and sonication of the complete lysate for maximum HA levels of 1:1024 to 1:2048 at 207 
day 3. 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
Figure 2. Production of NDV in CR.pIX cultures. (a) Lentogenic NDV enters CR.pIX cells but cannot spread without an 218 
exogenous supply with protease. (b) Adaptation of NDV by passaging on CR.pIX suspension cells. Note steep increase of 219 
infectious units between passage 4 and 5. (c) Differences in the kinetic of replication of the isolates at different passage 220 
levels, P4 and P9. (d) Influence of MOI on replication and yields. (e) Suspension cultures in a bioreactor infected with NDV. 221 
Addition of virus production medium CD-VP4 to 1/6-th of the culture volume induces small aggregates. CPE is evident 24 h PI. 222 
(f) Sonication further increases HA yields. PI, post infection. 223 
 224 
Avian infectious bronchitis 225 
 226 
Avian infectious bronchitis virus (IBV) belongs to the Coronaviridae, and therein to the 227 
Gammacoronavirus genus in the Coronavirinae subfamily. Coronaviruses are a family of large enveloped 228 
viruses with prominent surface proteins or spikes.  229 
 230 
IBV is disseminated by aerosol and fomites and mainly causes damage in the respiratory and the uro-231 
genital tract [14]. Overt direct or secondary bacterial disease has been observed only in galliforms 232 
[55,56] but waterfowl appears to be susceptible and may serve as asymptomatic reservoir for IBV if 233 
chicken and ducks are farmed together [57]. 234 
 235 
Vaccinations regimes typically include live and killed vaccines but infectious bronchitis appears to be a 236 
disease that is not easily controlled. The attenuated strains are generated by serial passages in eggs, and 237 
the final passage level of a vaccine virus is selected by balancing the safety and efficacy of the vaccine 238 
candidate virus [55].  239 
We were disappointed but not surprised that inoculation of CR or CR.pIX cell monolayers with IBV strains 240 
M41, H120 or 11518/2010 originated from 13-day-old broiler with severe lympho-histiocytic interstitial 241 
nephritis did not result in any signs of CPE (data not shown). IBV is known to replicate efficiently in 242 
embryonated eggs but not in continuous cell lines ([61] and references therein). The attenuated strain 243 
Beaudette, that was obtained by serial passaging in embryonated chicken eggs [62], is an exception with 244 
a broad cell tropism but reduced value as vaccine strain. 245 
 246 
One barrier for permissivity maps to the spike protein (S) of the viral particles [63,64]. This S protein of 247 
IBV is processed by cellular proteases into two subunits, S1 and S2 [65]. The S1 subunit mediates 248 
attachment to the target cell [58] and appears to contain the dominant positions for neutralizing 249 
epitopes and escape mutants [66]. The S2 subunit cooperates with the cognate S1 in receptor 250 
recognition and is responsible for fusion of viral and plasma membranes [14,67]. The receptors of IBV are 251 
not yet known but glycosylated structures, especially α-2,3-linked sialic acids, appear to be required for 252 
infection [14,65]. Both, α-2,3 and α-2,6 configurations are available on CR and CR.pIX cells (Figure 5 (a)). 253 
 254 
We attempted adaptation of the M41 and H120 strains to our culture system. Adaptation, however, 255 
requires at least low-level replication of the viruses so that suitable mutations can accumulate. 256 
Speculating that entry of viruses into the cells is the main block we also tested different mammalian cell 257 
lines (hoping for pseudoaffinity [61]) and added polymers (such as polybrene, poly-L-lysine and 258 
polyethylenimine) known to augment interaction of viruses (or lipid vesicles) with plasma membranes 259 
[68] (Figure 3 (a)). Potential infection was assayed by RT-PCR with primers against the ORF1a 260 
polyprotein. 261 
 262 
We detected a signal for genomic RNA in infected suspension cultures. This signal was maintained for 263 
one week, could be rescued into one subpassage, but was lost with the second subpassage (Figure 3 (b, 264 
c)). In adherent cultures we did not observe any signals indicative of entry of any viruses. One important 265 
difference in the handling of adherent and suspension cultures was that adherent cultures were washed 266 
2 h after inoculation with seed virus. Although interference by bovine serum present in the medium for 267 
adherent cultures is a formal possibility, we consider that detection of the input virus is the most 268 
parsimonious explanation for transient detection of viral genome and consistent with similar 269 
observations and reports on virus stability in the literature [56,69]. 270 
 271 
Combined, CR and CR.pIX cell lines appear not to be permissive for and probably not even susceptible to 272 
infection with IBV strains M41 or H120. Adaptation may be successful starting with a strain such as 273 
Beaudette but this may not be generally desirable. Adaption of IBV to replication ex vivo appears to 274 
change properties of the virus that may reduce cross-protection as a vaccine. S1-vectored vaccines may 275 
provide alternative vaccines against infectious bronchitits [14], so the muscovy duck cell lines may still 276 
find a way for IBV vaccines as producers of recombinant viral vectors[32]. 277 
 278 
 279 
 280 
 281 
 282 
Figure 3. No infection with IBV strains M41 and H120. (a) Adherent cultures of BHK (from the Syrian hamster), R05T (from the 283 
Egyptian fruit bat [70]) and CR.pIX cells were inoculated with AIBV at MOI of 1 also in presence of charged polymers with the 284 
intention to improve infection [68]. Potential entry of virus was analysed by RT-PCR. A comparison of infection of adherent 285 
(a) and suspension (s) cultures initially suggested that suspension cultures may be susceptible. (b) Strong signal in the 286 
suspension culture for 6 days but reduced signal of the first passage (performed with the culture 3 days post inoculation). (c) 287 
Complete loss of signal in inoculations with lysate from the previously inoculated CR.pIX culture. Passage 1 culture shown in 288 
(b) was lysed and used to inoculate fresh CR.pIX cells. No signal indicative of replication-competent virus could be detected 289 
suggesting that all earlier signals were caused by the virus from the initial inoculation. 290 
 291 
Marek's disease 292 
 293 
Marek's disease (MD) is a neoplastic disease caused by some herpesviruses of the Mardivirus genus. The 294 
type species is referred to as Gallid herpesvirus 2 (GaHV-2) or Marek's disease virus (MDV). Other species 295 
in this genus include Gallid herpersvirus 3 (GaHV-3) and Meleagrid herpesvirus 1 (MeHV-1), also referred 296 
to as herpesvirus of turkey (HVT). Infections with MDV lead to substantial economic losses each year, 297 
while GaHV-3 and HVT are non-pathogenic. 298 
 299 
MDV replicates in the skin and feather follicles and is disseminated horizontally via inhalation of fomites. 300 
Infiltration of neurons can cause progressive paralysis of legs and wings whereas diffuse lymphomatosis 301 
of visceral organs often presents as an acute disease associated with high mortality [71,72]. 302 
 303 
Vaccines against MD are based on live-attenuated strains of GaHV-2 (for example, Rispens strain), non-304 
pathogenic GaHV-3, and more importantly on non-pathogenic HVT. HVT is also widely used as vector 305 
virus, and with appropriate insert genes HVT represents the new generation of poultry vaccines being 306 
able to provide good protection against several important avian diseases such as Newcastle disease, 307 
avian influenza, infectious bronchitis or infectious laryngotracheitis. Vaccine roduction is usually 308 
performed in CEFs and occasionally in duck embryo fibroblasts [72]. Continuous cell lines reported to be 309 
permissive for mardiviruses include the DF-1 chicken cell line [77] and the QM7 quail muscle cell line 310 
[78]. The QT-35 quail fibrosarcoma cell line is also permissive at least for HVT but, surprisingly, appears 311 
to harbour also a previously uncharacterized latent virus possibly related to GaHV-2 [79]. Another cell 312 
line reported to be permissive is the chronically infected lymphoblastoid cell JM-1 that was derived from 313 
chickens infected with MDV and that can transmit this virus to CEFs in cocultivation experiments [80]. 314 
 315 
However, there are also unpredictable restrictions in the permissivity for mardiviruses in vitro. For 316 
example, MDV was shown not to replicate in the chicken cell line LSCC-H32 that is permissive for a wide 317 
spectrum of other viruses [48], and only a small fraction of cells, 5 %, were positive for viral antigens in 318 
the chronically infected JM-1 cultures [80]. Gene expression of latent MDV-like virus in QT-35 cells could 319 
be reactivated by superinfection with HVT but recovery of infectious units was not possible by 320 
cocultivation with CEFs or primary chicken kidney cultures [79]. Isolation was only successful in vivo by 321 
inoculation of QT-35 cells into chicken embryos [79]. 322 
 323 
We infected adherent CR and CR.pIX cultures with different mardiviruses, including HVT, a vector HVT 324 
that expresses an antigen to protect against NDV [81,82] (Vectormune ND, Ceva Animal Health), and 325 
Rispens. The results shown in Figure 4 (a) and (b) were obtained by inoculation with revitalized CEF cells 326 
carrying Vectormune ND where MOI indicates ratio of infected fibroblasts to CR or CR.pIX. Propagation 327 
of HVT was tracked by qPCR against the viral genome and the cellular DNA. 328 
 329 
 330 
 331 
 332 
 333 
Figure 4. Mardivirus propagation in adherent CR and CR.pIX cells. (a) CR and CR.pIX cells were inoculated with the freshly 334 
revitalized Vectormune ND preparation at the indicated ratios (for example, MOI of 0.1 corresponds to 1 CEF of the vaccine 335 
for every 10 cells of the anatine continuous cell line). The cultures were subpassaged twice per week by 5-fold dilution. DNA 336 
was isolated at each passage and qPCR was performed with primers against mardiviruses and against the E1A gene of the 337 
continuous cell line to normalize results to the number of host cells. CR cells are fully permissive for mardiviruses but several 338 
attempts failed to establish a productive infection in CR.pIX cells. (b) Immunofluorescence staining against HVT parent virus 339 
of Vectormue ND and the cellular E1A gene demonstrates extensive spread of HVT in a culture that has been subpassaged 340 
nine times. (c, d) Chronic infections could be maintained for 30 passages. CPE is characterized by extensive cell damage and 341 
large syncytia. (e, f) Both, CR and CR.pIX cells were fully permissive for the Rispens strain (GaHV-2). This virus induced strong 342 
CPE also in CR.pIX cells but replicated to lower levels. The dashed lines between passage 2 and 3 (CR only) and 5 and 6 (both 343 
cell lines) indicate addition of 1/10th of uninfected cells because cytopathic effect appeared to be too strong to continue 344 
subpassaging. The genome equivalents of Rispens were also determined with primers against pIX in the CR.pIX cultures; as 345 
expected, pIX could not be detected in CR cultures and the corresponding genome equivalents are therefore not shown. 346 
 347 
 348 
CR cells are fully permissive for HVT (Figure 4 (a) to (d)) and Rispens ((Figure 4 (e, f)) and infection leads 349 
to a progressively expanding CPE that is characterized by frequent plaque formation (centrally dislodged 350 
cell layer framed by highly refractile cells) or large syncitia. Appearance of CPE was delayed and is often 351 
negligible in the first 3 passages. Chronic infections were readily established and one culture was HVT-352 
positive for at least 30 passages until CPE developed to an extent that required addition of uninfected 353 
cells prior subpassage (Figure 4 (c, d)). Because of the delayed CPEs we did not titrate virus by TCID50 354 
protocols but quantified virus propagation via qPCR. The qPCR cycle threshold levels for the cellular E1A 355 
gene in the full lysates were used to normalize the number of viral genomes to the number of cells in the 356 
culture. With this quantitative measurement, that should be independent of cell numbers, we observed 357 
what appears to be a periodicity in the kinetic of virus propagation. The maximum yields and kinetic we 358 
observe for MDV and Rispens in adherent CR cultures compares well with previous results in chickens 359 
that measured a maximum of 108 HVT genomes per 106 feather follicle cells [73]. 360 
 361 
CR.pIX cells were not permissive for HVT but allowed productive propagation of Rispens with strong 362 
cytopathic effect yet lower titers compared to CR cells (Figure 4 (a, e)). Especially the block in HVT 363 
replication is very surprising because CR.pIX and CR cells differ only by the expression of the pIX protein 364 
[28], a minor structural and presumably also regulatory factor of human adenoviruses [83,84]. We have 365 
proposed previously that pIX may also augment binding of Hsp70 and Hsp90 in the avian cell line [28]. 366 
The resulting activation of the heat shock response can be beneficial for replication of some viruses 367 
[85,86] but may also elevate antiviral responses as signaling cascades of the two pathways communicate 368 
[87,88]. Mardiviruses have also been reported to interact with Hsp70 [89,90], and may depend on this 369 
factor for entry into chicken embryo fibroblasts [90]. By directing Hsp70 into complexes with Hsp90, pIX 370 
may interfere with availability of Hsp70 at the cell surface in a way that can be partially compensated by 371 
Rispens but not by HVT. Alternatively, pIX may indirectly cause an elevated state of innate immunity.  372 
HVT does not code for several virulence factors that are present in Rispens [91,92] and may therefore be 373 
unable to block the cellular defenses. (why is this grey????) 374 
 375 
Avian influenza 376 
 377 
Members of the Influenzavirus A genus in the Orthomyxoviridae family, the avian influenzaviruses (AIVs), 378 
are among those pathogens with a very high capacity to cause dangerous zoonosis and pandemics [93]. 379 
They can infect birds and mammals, and are transmitted by the respiratory route without dependence 380 
on hematophagous vectors. The diversity of viral strains is extremely broad and properties span low to 381 
high pathogenicity (with case fatality rates from 0.1 % to at least 15 % [94]), low to high transmissibility, 382 
and narrow to broad host range. 383 
 384 
AIV pathogenicity is determined by a number of factors that range from tropism (for example, viruses 385 
that infect the lower respiratory tract tend to cause more severe disease than those that replicate in the 386 
upper regions) to interaction with innate immunity (the case fatality rate is higher for strains that induce 387 
hypercytokinemia or "cytokine storms") [95,96]. Tropism and host range is mainly determined by the 388 
haemagglutinin and neuraminidase proteins (HA and NA, respectively) on the virion surface and the 389 
nonstructural protein PB2, a subunit of the viral RNA polymerase. A wide variety of strains have been 390 
used to protect against infection with H9N2, H5N2, H5N1, H7N3, H7N7 viruses in various parts of Asia, 391 
North America and North Africa [107]. Problems that are sometimes associated with the current 392 
production system are low yields for certain strains so that expensive concentration steps are necessary 393 
to increase potency, considerable amounts of egg shells that remain as biohazardous solid waste, and 394 
dependence on a continuous supply with embryonated eggs free of adventitious agents [107,109,110]. 395 
Improved control over supply with embryonated eggs is achieved by constructing breeding facilities 396 
immediately adjacent to the production site, but this comes at substantial costs [111]. We have 397 
therefore tested replication of H9N2 as a highly representative strain for LPAIVs in suspension cultures of 398 
CR.pIX cells to provide an additional production substrate that is independent of primary material (FIG 399 
5). 400 
 401 
Because the host spectrum of AIVs is partially determined by preference for 2,3 or 2,6 α-glycosidic 402 
linkage at the terminal sialic acid [103] we first characterised surface glycosylation of the CR and CR.pIX 403 
cell lines. Avian isolates tend to recognize 2,3 α-glycosidic bonds that predominate in the gastrointestinal 404 
and respiratory tract of ducks and chickens whereas human isolates tend to recognize the 2,6 α-405 
configuration that predominates in our upper respiratory tract [96,112]. Whereas early passage cell 406 
pools are not uniformly positive for the 2,6 α-configuration we observe that lectins specific for either 407 
confirguration yield signals in the final CR.pIX cell clone (FIG 5 (a)). This result suggests that AIV isolates 408 
should be able to replicate in CR.pIX cultures independent of a mammalian or avian origin, a property 409 
that has also been described for the MDCK cell line that is considered a gold standard in influenzavirus 410 
research [113,114]. 411 
 412 
Orthomyxoviruses require proteolytic activation of the viral receptor similar to the paramyxoviruses [43–413 
45]. The proteases contained in embryonated eggs are replaced by exogenous trypsin in cell cultures. We 414 
observed good replication of the two H9N2 isolates in the presence of 0.5 and 1.5 µg/mL of trypsin, well 415 
below the 2.5 µg/mL as maximum amount of trypsin that is tolerated by CR.pIX (FIG 5 (a)). Replication of 416 
both isolates (duck/1995 and turkey/1966) at passage level 2 appeared to be very fast with maximum 417 
titers in the range of 5 × 107 TCID50/mL and 1:256 HAU/100 µL within 24 h of infection. However, 418 
although both isolates are H9N2 strains they differed in maximum yields, a property that was maintained 419 
even after 10 passages in the CR.pIX cells (FIG 5(c)). Permissivity of CR.pIX cells appears to be very high as 420 
both isolates established productive infections to maximum titers at MOIs as low as 10-7 (FIG 5(c)). 421 
 422 
AIVs isolated with the help of cell lines have been proposed to be suitable as vaccine seeds [114]. The 423 
hemagglutinating and infectious activities of the LPAIV propagated in CR.pIX cells in true suspensions 424 
cultures in chemically-defined medium without microcarriers and at extremely low MOIs compare 425 
favourably to the results reported with H9N2 in MDCK cells [114,115]. 426 
 427 
 428 
 429 
Figure 5. Replication of LPAIV H9N2 isolates in CR.pIX cultures. (a) Lectin binding indicates that both terminal α-glycosidic 430 
sialic acid configurations utilized by influenza A viruses as receptor are available on CR.pIX suspension cells. The initial pool of 431 
cells appeared not uniformly positive for the 2,6 configuration. (b) Very fast replication of the two H9N2 isolates in the CR.pIX 432 
suspension cells to high titers in presence of low and high amounts of trypsin. (c) Infectious and hemagglutinating activity of 433 
passage 10 of the two isolates as function of MOI. 434 
 435 
Infectious bursal disease 436 
 437 
IBDV is a member of the Birnaviridae, genus Avibirnavirus. The disease caused by IBDV, infectious bursal 438 
disease (IB) or Gumboro disease, is a serious economic burden to the poultry industry [116]. Only 439 
chicken appear to be susceptible to overt disease; turkeys, ducks and other poultry appear not to be 440 
affected by IBDV [117]. Infected chickens develop an acute depression of the humoral immune response 441 
due to extensive lesions in the bursa of Fabricius. Such animals are more susceptible to secondary 442 
infections and fail to respond adequately to routine vaccination [76]. 443 
 444 
The viral capsids are icosahedral with diameters of 60-70 nm. They are not enveloped and contain two 445 
segments of double stranded RNA of 2.8 kbp and 3.4 kbp, respectively. The two structural proteins (VP2 446 
and VP3) are released by the viral protease (VP4) contained in the autocatalytically active tripartite 447 
polyprotein. The infectious virion is very stable in the environment [76]. Control of IBDV is furthermore 448 
complicated by the evolution of the pathogen towards greater antigenic diversity and increased 449 
virulence [76,117]. The preferred vaccine is live IBDV that has to be monitored for a correct level of 450 
attenuation: viral replication should be high enough to induce protective immunity also in the presence 451 
of maternal antibodies and against the emerging variant field strains but below levels that may lead to 452 
immunosupression. The challenges are being addressed by immune-complex vaccines, HVT-vectored 453 
VP2, and by prime/boost regimes using live and killed vaccines for high value animals such as breeder 454 
hens. 455 
 456 
IBDV (strain B87) replicated rapidly in adherent monolayers of CR.pIX cells (Figure 6 (a)). We observed 457 
prominent comet formation indicative of efficient release of viruses 24 h PI followed by widely scattered 458 
and overt CPE 48 h PI. The results in adherent cultures are confirmed by the high yields of infectious 459 
units in various suspension culture formats (Figure 6 (b)): IBDV replicated in single-cell suspensions as 460 
efficiently as in cultures with induced aggregates that were designed to support propagation of cell-461 
associated viruses [32]. Titers were also not increased by lysis of the cells in either of the culturing 462 
system suggesting that none or negligible infectious units remain within the host cell at the end of the 463 
replication cycle. 464 
 465 
Propagation of IBDV in single-cell suspension cultures was robust with high titers at MOIs of 0.1 or 0.05 466 
(lower MOIs did not increase yields) and at intermediate to high cell densities (2 - 4  × 106 CR.pIX 467 
cells/mL). For production processes yields beyond 1010 TCID50/mL can be expected 4 days post infection. 468 
 469 
 470 
 471 
Figure 6. Replication of IBDV in CR.pIX cells. (a) Immunofluorescence staining of infected adherent cell monolayers. IBDV 472 
replicates fast and causes formation of large comets. (b) Similar yields independent of culture format or harvest suggests 473 
robust replication. SN, supernatant; SCS, single-cell suspension; AGG, suspended aggregates. (c) Replication kinetic depending 474 
on MOI (left panel) and cell density at infection (right panel). 475 
 476 
 477 
Derzsy's disease 478 
 479 
Derzsy's disease appears to affect only geese and muscovy ducks, and has been described in Europe, Asia 480 
and North America ([118] and references therein). It is a highly contagious and economically damaging 481 
disease caused by strains of Goose parvovirus (GPV) and Muscovy duck parvovirus (MDPV), species in 482 
the Dependovirus genus in the Parvoviridae family. The small non-enveloped viruses are shed in large 483 
amounts by acutely infected birds and remain stable against environmental and thermal stress [119]. 484 
Disease can be subclinical in adult animals but is usually fatal in birds in the first month after hatching. 485 
The preferred vaccines are based on live attenuated viruses produced in primary duck embryo cells, and 486 
recently, a transformed (tumorigenic in nude mice) cell line [120–122]. 487 
 488 
We have previously described replication of a goose parvovirus [33] and here briefly confirm this result 489 
with an extension to successful propagation of MDPV (Figure 7). Although they are closely related, the 490 
two viruses had profoundly different properties. GPV was propagated easily and reached a maximum 491 
titer of 7.5 log TCID50/mL within one passage whereas MDPV required three passages of the infected 492 
cells to reach a maximum titer of 6.1 log10 TCID50 (Figure 7 (b)). Concentration of antigen and infectious 493 
units also appear not to be congruent in a comparision of the two viruses (Figure 7 (a, b)). For example, 494 
790 EU/mL (ElISA Units/ml How is it defined it should be mentioned in MaM) of antigen yield for GPV 495 
corresponds to a more than ten-fold higher infectious dose relative to MDPV in a sample with 3400 496 
EU/mL. Another difference is that yields are higher if infection with GPV is performed with a low MOI 497 
whereas titers of MDPV benefit from infection with a greater MOI. (Did you use the same sera in the 498 
ELISA and was it validated for the two viruses? The sera may not bind to the two virus with equal affinity. 499 
With other word just because you measure higher ELISA titer at one virus does not mean that you have 500 
higher quantity of that virus. ELISA of Derzsy should be in the MaM) 501 
 502 
In summary, the yields for both GPV and MDPV both compare favorably to a vaccine dose of 2.6 – 4.8 log 503 
TCID50 or _______ EU (<- WHAT IS TYPICAL FOR VACCINE!?) (I do not have the faintest idea Pénzes might 504 
know about it they have vaccine against Derzsy)  so that also for these viruses CR.pIX may provide a 505 
versatile production substrate to replace for the currently predominating primary cells. 506 
 507 
 508 
 509 
Figure 7. Propagation of goose (GPV) and muscovy duck parvoviruses (MDPV) in adherent CR.pIX cultures. (a) Yields of 510 
parvovirus antigens after infection with MOI of 0.1 or 0.01. (b) Infectious titers of the parvoviruses in CR.pIX cells. GPV 511 
replicates to expected titers within the first passage, MDPV replicates to high titers after three passages. All values shown 512 
were obtained from complete lysates 3 days post infection. 513 
 514 
Summary 515 
 516 
A delicate balance among costs , economic benefits and biological risk guides the decision on whether a 517 
given vaccine is or is not to be used for agricultural animals with a short life-span. One complication 518 
introduced into these considerations for poultry vaccines is that industrial farmers and those with low 519 
resources both require a diversity of vaccines, but that robust and cost-effective production appears to 520 
be skewed primarily towards industrial use. 521 
 522 
Most poultry vaccines are manufactured with material derived from embryonated eggs of a high quality. 523 
Dependence on embryonated eggs introduces costs and sometimes fragile logistics into vaccine 524 
production processes that could be circumvented if a continuous cell line permissive for a broad 525 
selection of vaccine strains and suitable for vaccine production were available. CR and CR.pIX are well 526 
characterized established cell lines for research and for manufacturing of vaccines. They are available as 527 
adherent cultures and in suspension format in chemically defined media without dependence on bovine 528 
sera or other animal-derived components. We now extend earlier studies on permissivity for various 529 
pathogens to include several poultry vaccine candidates against egg drop syndrome, Marek's disease, 530 
Newcastle disease, infectious bronchitis, avian influenza, infectious bursal disease, and Derzsy's disease. 531 
Some of the viruses presented unique requirements for the production process but all, with exception of 532 
the two isolates of IBV, could be propagated to high titers in the anatine continuous cell lines. Future 533 
studies will focus on two major aspects, one being scale-up to larger bioreactors or transfer to different 534 
bioreactor types such as cultivation at high cell-density or with help of perfusion. The other important 535 
topics are characterization of safety and immunogenicity of vaccines obtained after the change of the 536 
active substance and the production protocol. 537 
 538 
Material and methods 539 
 540 
Cells and viruses 541 
 542 
The CR and CR.pIX cell lines and the development of the chemically defined media has been described 543 
previously [28,32]. The CD-U3 and CD-VP4 media used in this study were manufactured by Biochrom 544 
(catalog numbers F9185 and F9127, respectively). Viruses were obtained from Ceva Phylaxia (Hungary) 545 
and the Friedrich-Löffler-Institut (Germany). 546 
 547 
Determination of infectious units 548 
 549 
Infectious titers of NDV and H9N2 were determined on Vero cells. 2 × 105 cells in DMEM:F12 medium 550 
containing 2 mM GlutaMAX I (both Gibco) and 5 % fetal calf serum (Biochrom) were seeded into a 96-551 
well plate at 100 µL of cell suspension. The medium was replaced on the following day against 552 
DMEM:F12 containing 2 mM GlutaMAX I and 1.5 µg/mL trypsin (type IX-S, Sigma T0303), but no fetal calf 553 
serum. Serial dilutions in steps of 10 of NDV or H9N2-containing virus samples were prepared in 554 
DMEM:F12 medium free of serum, and 10 µL each of the dilutions were added to the Vero cultures. 555 
Virus replication was allowed at 37 °C for 72 h. 556 
 557 
Detection of NDV or H9N2 replication was facilitated by immunostaining: the cells were fixed in 558 
methanol for 10 min, allowed to dry to completion, and rehydrated with PBS containing 0.05 % Tween-559 
20. NDV antibody (CSI) or H9-antiserum (GD Animal Health, VLDIA150) were added to a dilution of 560 
1:2000 in PBS containing 1 % fetal calf serum and incubated for 1 h at room temperature. After two 561 
washes with PBS, secondary antibody (anti-chicken, Alexa Fluor 488 labelled, host rabbit, _________) 562 
was added at a dilution of 1:2000 for 2 h at ambient temperature or overnight at 4 °C. Infected wells 563 
were identified by fluorescence after two washes with PBS. Calculation of TCID50 values was performed 564 
according to Spearman and Kärber using the implementation of the FAO [123,124]. 565 
 566 
Infectious titers of EDSV were determined on CS cells, a fibroblastoid and strictly adherent relative of the 567 
CR cell line [28]. Similar to titration of NDV, indicator cells were seeded (at 1 × 106 cells/plate) one day 568 
prior to infection. Virus samples were applied in 10-fold serial dilutions without change of medium or 569 
addition of trypsin, and replication was allowed for 3 days at 37 °C. Identification of infected wells was 570 
facilitated by immunostaining with primary antibody (GD Animal Health, VLDIA050) at 1:2000 and 571 
secondary antibody conjugated to Alexa Fluor 488 at 1:2000 after fixation with methanol. 572 
 573 
IBDV titers were determined on adherent CR.pIX cells. Infection was performed with samples in 10-fold 574 
serial dilutions, one day after the indicator cells were seeded at 4 × 106 per 96-well plate. Wells with CPE 575 
were identified microscopically (without immunostaining) 3 days post infection. As for EDSV, a change of 576 
medium or addition of trypsin was not performed to titer this virus. 577 
 578 
Haemagglutination assay 579 
 580 
Haemagglutination units (HAU) as correlates for number of viral particles were determined with chicken 581 
erythrocytes and serial dilutions of infected cell suspensions in PBS in steps of 2. The erythrocytes were 582 
isolated from complete blood of what?. Briefly, erythrocytes in 7 mL of a complete blood suspension (25 583 
% in alsever buffer, E200, Labor Dr. Merk & Kollegen GmbH, Germany) were washed thrice in PBS. 584 
Centrifugation for the washing steps was performed at room temperature with 500 × g, brake set to low, 585 
for 5 min each. The final erythrocyte suspension was diluted in PBS to a concentration that yields an OD 586 
of 2.9-3.1 at 576 nm. This suspension was stored for up to 2 weeks at 4 °C. 587 
 588 
The assay was performed in round-bottom 96-well microtiter plaes. The first row of the plate was filled 589 
with 200 µL of the infected cell suspension (wa it claridfied or it contained cells too?) and all other rows 590 
received 100 µL of PBS. Next, 100 µL of virus sample was added to the second row, the pipetting tips 591 
were replaced and the suspension mixed with fresh tips. This two-fold dilution was continued serially 592 
into the next row, and, for samples with high potency, continued into a second plate. Each well thus 593 
contained 100 µL of diluted virus sample and was subsequently supplemented with 100 µL of the 594 
erythrocyte suspension. This volume was mixed by pipetting and the turbid solution allowed to stand 595 
undisturbed for 30 min at ambient temperature (22 °C). HAU/100 µL are given by the highest dilution 596 
where formation of a dot was visible. 597 
 598 
Some samples were further homogenized by sonication with a sonotrode H3 (Hielscher, Germany) of 3 599 
mm diameter powered by an UP400S device at 50 % pulse and 50 % amplitude for 5 min (100 mL). This 600 
step increased HA titers of NDV by 2 to 4 dilution steps but was not performed in all experiments. 601 
 602 
Detection and titration by qPCR 603 
 604 
DNA was isolated with the QIAamp DNA Blood Mini kit (Qiagen). Purified DNA was eluted into 100 µL, 605 
and 5 µL thereof were added to PCR reactions. Alternatively, DNA was isolated from 20 µL of infected 606 
cell culture suspension by addition of 5 µL of QuickExtract DNA Extraction Solution 1.0 (101094, Biozym). 607 
This sample was heated to 65 °C for 15 min and to 98 °C for 5 min. After dilution with 50 µL of water, 8 608 
µL therefrom???????? was added to a PCR reaction with a final volume of 20 µL. 609 
 610 
Quantitative PCR of EDSV was performed using the Power SYBR Green PCR Master Mix (Applied 611 
Biosystems) in an ABI 7000 unit. Primers were added to 70 nM each per reaction and real-time PCR was 612 
launched with a single incubation for 10 min at 95 °C, followed by 40 cycles of 94 °C for 15 seconds and 613 
60 °C for 1 min. The primer sequences were TgA CTC Cgg TCC TTC TAA CAC A and TCA Cgg CAA CTg gTT 614 
TAA Tgg for detection of the E1A gene used to immortalize the avian host cell as internal reference [28], 615 
and gAg CgT gAT CAA gTC gAT gg and CAC TTA CCg CgA gCA TAT CC against the polymerase of EDSV 616 
(designed using GenBank sequence with accession number Y09598). Amplification of the genomic DNA 617 
was calculated via an adaptation described previously for relative quantification of gene expression [37]. 618 
We first determined the differences in the ct values obtained with primers against viral genome and 619 
against cellular DNA relative to the first data point, usually 2 h post infection. The differences were raised 620 
to the power of 2, assuming a uniform efficiency of 2.0 for each cycle of amplification, and the ratios of 621 
changes of viral to cellular DNA, each relative to the first data point, is the burst number. 622 
 623 
HVT titers were calculated similarly, but here, because of the seeding with HVT infected CEFs that do not 624 
contain a cellular reference, we did not normalize to an arbitrary initial time of infection, but rather 625 
depicted the ratio of viral to cellular DNA (as "genome equivalents") for each passage. The primers used 626 
to detect E1A were the same that were used in the EDSV study and primers against the cellular pIX gene 627 
were ACC TAC gAg ACC gTg TCT g and gAg CCg TCA ACT TgT CAT C, but primers were added to 90 nM 628 
each. The primer sequences were TCg gCg CCC TTT gAT ATA CT and TAg Agg AAg TgT Tgg gCA gg (against 629 
the HVT012 gene of MeHV-1, Genbank AF291866), and TCCgTCgTgAATTTgTACgC and CgA CAA TTC CAC 630 
CTT Agg Cg (against the MDV011 gene of GaHV-2, Genbank DQ530348). 631 
 632 
RNA-extraktion was performed with the Innu PREP RNA Mini kit (Analytik Jena) and cDNA transcribed 633 
with the Cloned AMV First-Strand cDNA-Synthesis kit (Invitrogen) using random hexamers. PCR was 634 
performed with 2.5 µL of the cDNA in 25 µL reactions with 94 °C for 180 s, followed by 35 cycles of 94 °C 635 
for 30 s, 57 °C for 30 s and 72 °C for 60 s. Conventional PCR was performed with 2.5 µL sample in 25 µL 636 
reactions with the thermocycler programmed to 94 °C for 180 seconds, followed by 30 cycles at 94 °C for 637 
30 s, 55 °C for 30 s and 72 °C for 60s. A fragment of IBDV genomic RNA segment B was amplified with 638 
primers gAC gAg TTC CTA gCC gAg Tg and CTg gCT gTg gCT AgA Agg AC. The primers bind to what appear 639 
to be conserved islands determined by alignment of GenBank sequences JQ411013 (isolate Hungary 640 
903/78), GQ451331 (strain HLJ-0504), JX682710 (isolate QL), FJ695139 (Chinese strain YS07), and 641 
JX682712 (strain ZZ-11). H9N2 genome was quantified with AAg CCg AAA TCC Tgg gAA Tg and CTC CCT 642 
CTC AAA gTC gTA TC against segment 5 encoding NP (Genbank DQ067440), and IBV was detected with 643 
TgT TgT gCC AgT CCT CTC AT and gTT TCA CAg TAg CAg AgC gg against the ORF1a gene of strain H120 644 
(Genbank FJ888351). 645 
 646 
 647 
Lectin staining 648 
 649 
Cells were collected with 200 × g, fixed with 1 % formaldehyde in PBS and incubated with 30 µg/mL of 650 
biotinylated agglutinin of Sambucus nigra (Vector Laboratories, USA, B-1305) to detect α 2,6 bonds, or of 651 
Maackia amurensis (B-1265) to detect α 2,3 bonds on the surface of the plasma membrane (the cells 652 
were not permeabilized). Binding was allowed for 45 min at ambient temperature and protected from 653 
light. The cells were washed once with PBS and the bound lectins were visualized with streptavidin 654 
conjugated to Texas Red (016-070-084) or fluorescein (DTAF, both from Jackson Immuno Research, 655 
#016-010-084). DAPI (4',6-diamidino-2-phenylindol ) in methanol was added to 1 µg/mL as a nuclear 656 
counterstain. The cells were washed once more with PBS prior to fluorescence microscopy. 657 
 658 
Bioreactor 659 
 660 
The DASBox (DASGip, Eppendorf) bioreactor units were equipped with a Marine impeller with 3 blades 661 
and 60-250 mL working-volume vessels. Gas mixing was performed with N2, air, CO2 and O2, pH was 662 
adjusted with CO2 and 1 M Na2CO3. Inoculation was usually performed to 1 × 10
6 cells/mL in CD-U3 663 
medium and the culture was allowed to proliferate for 3 days to approximately 4 × 106 cells/mL. The 664 
parameters for the cell proliferation phase were 37 °C culture temperature, 60 % DO  (dissolved 665 
Oxigen????) saturation in the medium, 150 rpm for the impeller, and a pH gradient that decreased from 666 
7.25 to 7.00 units in the cell culture during cell proliferation. The pH was usually kept at 7.0 units during 667 
infection and impeller speed was increased to 180 rpm. 668 
 669 
Variations were introduced by addition of one volume of virus production medium (100 mL, fed at a rate 670 
of 40 mL/h) 2 days after infection to cultures infected with EDSV, and 1/6th volume at the time of 671 
infection with NDV. Propagation of NDV and H9N2 virus was furthermore supported by feeding trypsin 672 
(type IX-S, Sigma T0303) into the infected culture from a 1 mg/mL, 16 U/µL solution at 0.17 mL/h, 4 mL 673 
per day for a final concentration of 0.5 µg/mL of reactor volume per day. Recombinant trypsin (rTrypsin, 674 
Novozym 6395020) was fed into the infected culture from a solution kept at 4 °C with an activity 675 
adjusted such that a feeding rate of 0.17 mL/h (4 mL per day) resulted in a final concentration of 8 U/mL 676 
of culture volume each day. Recombinant or porcine trypsin were equivalent in activity. The incubation 677 
temperature was set to 35 °C for propagation of NDV. None of the mardiviruses replicated in suspension 678 
cultures, also not if the cultures were supplemented with virus production medium or bovine serum. 679 
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